Trump Administration Reclassifies Cannabis as Less Dangerous

Why It Matters

Reclassifying cannabis to Schedule III eases research barriers and could soften banking and tax constraints for the burgeoning industry, influencing future federal legalization debates.

Key Takeaways

• DOJ moves certain cannabis products to Schedule III, aligning with codeine
• Acting AG Todd Blanche ordered a June hearing for broader reclassification
• Change follows Trump’s executive order to expand medical psychedelic access
• Federal schedule shift may ease research, banking and tax constraints

Pulse Analysis

The rescheduling of cannabis marks the most significant federal policy adjustment since the 1970 Controlled Substances Act placed marijuana in Schedule I, a category reserved for substances with high abuse potential and no accepted medical use. President Trump’s 2023 executive order set the stage, and Acting Attorney General Todd Blanche’s recent announcement fulfills that mandate for FDA‑approved and state‑licensed medical products. By moving these items to Schedule III, the Justice Department aligns cannabis with drugs like codeine, a move that historically permits tighter regulation while allowing legitimate medical research.

For the cannabis industry, the schedule shift could be a game‑changer. Schedule III status relaxes some of the stringent reporting requirements that have hampered clinical trials, potentially accelerating data on safety and efficacy. Moreover, banks and financial institutions, which have long avoided cannabis firms due to the Schedule I designation, may view the new classification as a reduced compliance risk. While the federal ban on recreational use persists, the change may also soften the notorious Section 280E tax burden, giving companies more leeway to claim ordinary business deductions.

Politically, the move underscores a bipartisan acknowledgment that the existing framework is out of step with public opinion—over two‑thirds of Americans now support full legalization. However, the rule will face legal challenges and could be stalled for months, mirroring past DEA postponements. Advocacy groups like NORML see the reclassification as a foothold for broader reform, while opponents warn it could open the door to premature commercialization. The coming months will reveal whether this symbolic step translates into substantive policy shifts or remains a procedural footnote.